ANI Pharmaceuticals (NASDAQ:ANIP) CFO Stephen Carey Sells 2,850 Shares of Stock

ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) CFO Stephen Carey sold 2,850 shares of the business’s stock in a transaction dated Wednesday, July 29th. The stock was sold at an average price of $81.36, for a total transaction of $231,876.00. Following the sale, the chief financial officer owned 174,693 shares in the company, valued at $14,213,022.48. This trade represents a 1.61% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

ANI Pharmaceuticals Trading Down 1.7%

NASDAQ ANIP opened at $80.43 on Friday. The company has a debt-to-equity ratio of 1.06, a quick ratio of 2.52 and a current ratio of 3.12. The firm has a market cap of $1.83 billion, a price-to-earnings ratio of 20.36 and a beta of 0.43. The firm has a 50 day simple moving average of $81.20 and a 200-day simple moving average of $79.52. ANI Pharmaceuticals, Inc. has a one year low of $62.60 and a one year high of $99.50.

ANI Pharmaceuticals (NASDAQ:ANIP) last announced its earnings results on Friday, May 8th. The specialty pharmaceutical company reported $2.05 earnings per share for the quarter, topping the consensus estimate of $1.28 by $0.77. ANI Pharmaceuticals had a net margin of 9.98% and a return on equity of 27.51%. The firm had revenue of $237.46 million for the quarter, compared to the consensus estimate of $207.63 million. During the same period in the prior year, the firm earned $1.70 EPS. The firm’s revenue for the quarter was up 20.5% on a year-over-year basis. ANI Pharmaceuticals has set its FY 2026 guidance at 9.190-9.690 EPS. Equities research analysts anticipate that ANI Pharmaceuticals, Inc. will post 8.03 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several research analysts recently commented on ANIP shares. Weiss Ratings raised ANI Pharmaceuticals from a “hold (c+)” rating to a “buy (b-)” rating in a research note on Tuesday, June 23rd. Wall Street Zen upgraded ANI Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research note on Saturday, May 9th. Canaccord Genuity Group assumed coverage on ANI Pharmaceuticals in a research report on Thursday, July 16th. They set a “hold” rating and a $91.00 price objective for the company. Zacks Research downgraded ANI Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Thursday, May 14th. Finally, Guggenheim restated a “buy” rating and set a $124.00 target price on shares of ANI Pharmaceuticals in a research note on Friday, July 10th. Six analysts have rated the stock with a Buy rating and three have given a Hold rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $105.00.

Institutional Trading of ANI Pharmaceuticals

Institutional investors have recently bought and sold shares of the business. Vanguard Group Inc. increased its holdings in shares of ANI Pharmaceuticals by 2.2% in the 4th quarter. Vanguard Group Inc. now owns 1,305,068 shares of the specialty pharmaceutical company’s stock valued at $103,022,000 after acquiring an additional 27,598 shares during the last quarter. State Street Corp lifted its stake in ANI Pharmaceuticals by 2.2% during the fourth quarter. State Street Corp now owns 727,204 shares of the specialty pharmaceutical company’s stock worth $57,405,000 after purchasing an additional 15,496 shares during the last quarter. UBS Group AG lifted its stake in ANI Pharmaceuticals by 45.8% during the third quarter. UBS Group AG now owns 589,874 shares of the specialty pharmaceutical company’s stock worth $54,032,000 after purchasing an additional 185,172 shares during the last quarter. Arrowstreet Capital Limited Partnership lifted its stake in ANI Pharmaceuticals by 19.3% during the first quarter. Arrowstreet Capital Limited Partnership now owns 564,360 shares of the specialty pharmaceutical company’s stock worth $43,399,000 after purchasing an additional 91,153 shares during the last quarter. Finally, Dimensional Fund Advisors LP boosted its holdings in ANI Pharmaceuticals by 8.9% in the first quarter. Dimensional Fund Advisors LP now owns 531,190 shares of the specialty pharmaceutical company’s stock valued at $40,843,000 after purchasing an additional 43,523 shares in the last quarter. 76.05% of the stock is owned by hedge funds and other institutional investors.

About ANI Pharmaceuticals

ANI Pharmaceuticals, Inc is a United States–based specialty pharmaceutical company focused on the development, manufacturing and commercialization of generic and branded prescription drugs. The company operates as an end-to-end provider, offering services that range from active pharmaceutical ingredient (API) production and formulation development to finished dosage form manufacturing and packaging.

ANI’s product portfolio encompasses injectable and oral therapies across several therapeutic areas, including endocrinology, oncology, pain management and respiratory care.